Protein kinase C inhibition in the treatment of mania: A double-blind, placebo-controlled trial of tamoxifen

Ayşegül Yildiz, Sebnem Guleryuz, Donna P Ankerst, Dost Öngür, Perry F. Renshaw

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

Context: Findings that protein kinase C (PKC) activity may be altered in mania, and that both lithium carbonate and valproate sodium inhibit PKC-associated signaling in brain tissue, encourage development of PKC inhibitors as candidate antimanic agents. Objective: To perform a controlled test of antimanic efficacy of the centrally active PKC inhibitor tamoxifen citrate. Design: Three-week, randomized, double-blind, placebo-controlled, parallel-arms trial. Setting: A university medical center inpatient psychiatric unit in Izmir, Turkey. Patients: Sixty-six patients aged 18 to 60 years, diagnosed as having DSM-IV bipolar I disorder on the basis of the Structured Clinical Interview for DSM-IV, currently in a manic or mixed state, with or without psychotic features, with initial scores on the Young Mania Rating Scale (YMRS) greater than 20. Intervention: Treatment with tamoxifen or identical placebo tablets for up to 3 weeks. Adjunctive lorazepam was allowed up to 5 mg/d. Main Outcome Measures: Primary: change in YMRS scores; secondary: change in Clinical Global Impressions-Mania scores, weekly ratings of depression and psychosis, and adjunctive use of lorazepam. Results: The 21-day trial was completed by 29 of 35 subjects randomized to receive tamoxifen (83%) and 21 of 31 given placebo (68%) (P=.25). Intent-to-treat analysis of available measures on all 66 subjects indicated that tamoxifen treatment yielded mean decreases in scores on the YMRS and Clinical Global Impressions-Mania of 5.84 and 0.73 point per week, respectively, compared with mean increases of 1.50 and 0.10 point per week, respectively, with placebo; both drug-placebo contrasts differed significantly (P<.001). Conclusions: Tamoxifen demonstrated antimanic properties and was remarkably well tolerated. The findings encourage further clarification of the role of PKC in the pathophysiologic mechanism of bipolar I disorder and development of novel anti-PKC agents as potential antimanic or mood-stabilizing agents. Trial Registration: clinicaltrials.gov Identifier: NCT00411203 and isrctn.org Identifier: ISRCTN97160532.

Original languageEnglish (US)
Pages (from-to)255-263
Number of pages9
JournalArchives of General Psychiatry
Volume65
Issue number3
DOIs
StatePublished - Mar 2008
Externally publishedYes

Fingerprint

Tamoxifen
Bipolar Disorder
Protein Kinase C
Antimanic Agents
Placebos
Lorazepam
Protein C Inhibitor
Therapeutics
Protein Kinase Inhibitors
Diagnostic and Statistical Manual of Mental Disorders
Lithium Carbonate
Inhibition (Psychology)
Excipients
Valproic Acid
Turkey
Psychotic Disorders
Tablets
Psychiatry
Inpatients
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Protein kinase C inhibition in the treatment of mania : A double-blind, placebo-controlled trial of tamoxifen. / Yildiz, Ayşegül; Guleryuz, Sebnem; Ankerst, Donna P; Öngür, Dost; Renshaw, Perry F.

In: Archives of General Psychiatry, Vol. 65, No. 3, 03.2008, p. 255-263.

Research output: Contribution to journalArticle

Yildiz, Ayşegül ; Guleryuz, Sebnem ; Ankerst, Donna P ; Öngür, Dost ; Renshaw, Perry F. / Protein kinase C inhibition in the treatment of mania : A double-blind, placebo-controlled trial of tamoxifen. In: Archives of General Psychiatry. 2008 ; Vol. 65, No. 3. pp. 255-263.
@article{9649addca7dc4713867ddb0df94528f6,
title = "Protein kinase C inhibition in the treatment of mania: A double-blind, placebo-controlled trial of tamoxifen",
abstract = "Context: Findings that protein kinase C (PKC) activity may be altered in mania, and that both lithium carbonate and valproate sodium inhibit PKC-associated signaling in brain tissue, encourage development of PKC inhibitors as candidate antimanic agents. Objective: To perform a controlled test of antimanic efficacy of the centrally active PKC inhibitor tamoxifen citrate. Design: Three-week, randomized, double-blind, placebo-controlled, parallel-arms trial. Setting: A university medical center inpatient psychiatric unit in Izmir, Turkey. Patients: Sixty-six patients aged 18 to 60 years, diagnosed as having DSM-IV bipolar I disorder on the basis of the Structured Clinical Interview for DSM-IV, currently in a manic or mixed state, with or without psychotic features, with initial scores on the Young Mania Rating Scale (YMRS) greater than 20. Intervention: Treatment with tamoxifen or identical placebo tablets for up to 3 weeks. Adjunctive lorazepam was allowed up to 5 mg/d. Main Outcome Measures: Primary: change in YMRS scores; secondary: change in Clinical Global Impressions-Mania scores, weekly ratings of depression and psychosis, and adjunctive use of lorazepam. Results: The 21-day trial was completed by 29 of 35 subjects randomized to receive tamoxifen (83{\%}) and 21 of 31 given placebo (68{\%}) (P=.25). Intent-to-treat analysis of available measures on all 66 subjects indicated that tamoxifen treatment yielded mean decreases in scores on the YMRS and Clinical Global Impressions-Mania of 5.84 and 0.73 point per week, respectively, compared with mean increases of 1.50 and 0.10 point per week, respectively, with placebo; both drug-placebo contrasts differed significantly (P<.001). Conclusions: Tamoxifen demonstrated antimanic properties and was remarkably well tolerated. The findings encourage further clarification of the role of PKC in the pathophysiologic mechanism of bipolar I disorder and development of novel anti-PKC agents as potential antimanic or mood-stabilizing agents. Trial Registration: clinicaltrials.gov Identifier: NCT00411203 and isrctn.org Identifier: ISRCTN97160532.",
author = "Ayşeg{\"u}l Yildiz and Sebnem Guleryuz and Ankerst, {Donna P} and Dost {\"O}ng{\"u}r and Renshaw, {Perry F.}",
year = "2008",
month = "3",
doi = "10.1001/archgenpsychiatry.2007.43",
language = "English (US)",
volume = "65",
pages = "255--263",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Protein kinase C inhibition in the treatment of mania

T2 - A double-blind, placebo-controlled trial of tamoxifen

AU - Yildiz, Ayşegül

AU - Guleryuz, Sebnem

AU - Ankerst, Donna P

AU - Öngür, Dost

AU - Renshaw, Perry F.

PY - 2008/3

Y1 - 2008/3

N2 - Context: Findings that protein kinase C (PKC) activity may be altered in mania, and that both lithium carbonate and valproate sodium inhibit PKC-associated signaling in brain tissue, encourage development of PKC inhibitors as candidate antimanic agents. Objective: To perform a controlled test of antimanic efficacy of the centrally active PKC inhibitor tamoxifen citrate. Design: Three-week, randomized, double-blind, placebo-controlled, parallel-arms trial. Setting: A university medical center inpatient psychiatric unit in Izmir, Turkey. Patients: Sixty-six patients aged 18 to 60 years, diagnosed as having DSM-IV bipolar I disorder on the basis of the Structured Clinical Interview for DSM-IV, currently in a manic or mixed state, with or without psychotic features, with initial scores on the Young Mania Rating Scale (YMRS) greater than 20. Intervention: Treatment with tamoxifen or identical placebo tablets for up to 3 weeks. Adjunctive lorazepam was allowed up to 5 mg/d. Main Outcome Measures: Primary: change in YMRS scores; secondary: change in Clinical Global Impressions-Mania scores, weekly ratings of depression and psychosis, and adjunctive use of lorazepam. Results: The 21-day trial was completed by 29 of 35 subjects randomized to receive tamoxifen (83%) and 21 of 31 given placebo (68%) (P=.25). Intent-to-treat analysis of available measures on all 66 subjects indicated that tamoxifen treatment yielded mean decreases in scores on the YMRS and Clinical Global Impressions-Mania of 5.84 and 0.73 point per week, respectively, compared with mean increases of 1.50 and 0.10 point per week, respectively, with placebo; both drug-placebo contrasts differed significantly (P<.001). Conclusions: Tamoxifen demonstrated antimanic properties and was remarkably well tolerated. The findings encourage further clarification of the role of PKC in the pathophysiologic mechanism of bipolar I disorder and development of novel anti-PKC agents as potential antimanic or mood-stabilizing agents. Trial Registration: clinicaltrials.gov Identifier: NCT00411203 and isrctn.org Identifier: ISRCTN97160532.

AB - Context: Findings that protein kinase C (PKC) activity may be altered in mania, and that both lithium carbonate and valproate sodium inhibit PKC-associated signaling in brain tissue, encourage development of PKC inhibitors as candidate antimanic agents. Objective: To perform a controlled test of antimanic efficacy of the centrally active PKC inhibitor tamoxifen citrate. Design: Three-week, randomized, double-blind, placebo-controlled, parallel-arms trial. Setting: A university medical center inpatient psychiatric unit in Izmir, Turkey. Patients: Sixty-six patients aged 18 to 60 years, diagnosed as having DSM-IV bipolar I disorder on the basis of the Structured Clinical Interview for DSM-IV, currently in a manic or mixed state, with or without psychotic features, with initial scores on the Young Mania Rating Scale (YMRS) greater than 20. Intervention: Treatment with tamoxifen or identical placebo tablets for up to 3 weeks. Adjunctive lorazepam was allowed up to 5 mg/d. Main Outcome Measures: Primary: change in YMRS scores; secondary: change in Clinical Global Impressions-Mania scores, weekly ratings of depression and psychosis, and adjunctive use of lorazepam. Results: The 21-day trial was completed by 29 of 35 subjects randomized to receive tamoxifen (83%) and 21 of 31 given placebo (68%) (P=.25). Intent-to-treat analysis of available measures on all 66 subjects indicated that tamoxifen treatment yielded mean decreases in scores on the YMRS and Clinical Global Impressions-Mania of 5.84 and 0.73 point per week, respectively, compared with mean increases of 1.50 and 0.10 point per week, respectively, with placebo; both drug-placebo contrasts differed significantly (P<.001). Conclusions: Tamoxifen demonstrated antimanic properties and was remarkably well tolerated. The findings encourage further clarification of the role of PKC in the pathophysiologic mechanism of bipolar I disorder and development of novel anti-PKC agents as potential antimanic or mood-stabilizing agents. Trial Registration: clinicaltrials.gov Identifier: NCT00411203 and isrctn.org Identifier: ISRCTN97160532.

UR - http://www.scopus.com/inward/record.url?scp=40349093181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40349093181&partnerID=8YFLogxK

U2 - 10.1001/archgenpsychiatry.2007.43

DO - 10.1001/archgenpsychiatry.2007.43

M3 - Article

C2 - 18316672

AN - SCOPUS:40349093181

VL - 65

SP - 255

EP - 263

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 3

ER -